person · Reporting owner

Jenkins Annalisa

Disclosed activity across 8 companies

Tapewire entity: 54212
SEC CIK: 0001639481

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
ARDELYX, INC.ARDX · Entity 4972	Director	June 13, 2019	June 17, 2019
COMPASS Pathways plcCMPS · Entity 4567	Director	June 12, 2025	June 13, 2025
Mereo BioPharma Group plcMREO · Entity 7264	Director	February 26, 2026	February 27, 2026
ONCOSEC MEDICAL IncONCS · Entity 117092	Director	September 05, 2017	September 05, 2017
Serina Therapeutics, Inc.AGE · Entity 9581	Director	June 21, 2021	June 24, 2021
Skye Bioscience, Inc.SKYE · Entity 8098	Director	March 31, 2026	April 02, 2026
Tectonic Therapeutic, Inc.AVRO · Entity 5328	Director	June 06, 2023	June 08, 2023

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

ARDELYX, INC.

Report date June 13, 2019 · Filed June 17, 2019

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	33,471	Reported balance After 2019-06-13 transaction · row 1 1 source row Row 1 · 2019-06-13 · Grant · Acquired 20,072 · Balance 33,471 F1: The shares were issued pursuant to the Issuer's Non-Employee Director Compensation Program. The Reporting Person elected to receive stock in lieu of cash as permitted under the program.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.74 · Expires 2029-06-13	Direct	50,000	Reported balance After 2019-06-13 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2019-06-13 · Grant · Acquired 50,000 · Balance 50,000 F2: The option was issued pursuant to the Issuer's Non-Employee Director Compensation Program. F3: The option vests with respect to 1/12th of the shares subject thereto on each monthly anniversary of the grant date, which vesting will accelerate in full on the date of the next annual stockholder's meeting to the extent unvested as of such date, subject to continued service through each applicable vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: The shares were issued pursuant to the Issuer's Non-Employee Director Compensation Program. The Reporting Person elected to receive stock in lieu of cash as permitted under the program.

F2: The option was issued pursuant to the Issuer's Non-Employee Director Compensation Program.

F3: The option vests with respect to 1/12th of the shares subject thereto on each monthly anniversary of the grant date, which vesting will accelerate in full on the date of the next annual stockholder's meeting to the extent unvested as of such date, subject to continued service through each applicable vesting date.

COMPASS Pathways plc

Report date June 12, 2025 · Filed June 13, 2025

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Share Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.52 · Expires 2035-06-11	Direct	26,000	Reported balance After 2025-06-12 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2025-06-12 · Grant · Acquired 26,000 · Balance 26,000 F1: The shares underlying this option vest in full upon the earlier to occur of (i) the first anniversary of the date of grant or (ii) the date of COMPASS Pathways plc's Annual General Meeting of Shareholders in 2026. F2: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

Filing footnotes · ownership attribution and instrument terms

F1: The shares underlying this option vest in full upon the earlier to occur of (i) the first anniversary of the date of grant or (ii) the date of COMPASS Pathways plc's Annual General Meeting of Shareholders in 2026.

F2: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

Mereo BioPharma Group plc

Report date February 26, 2026 · Filed February 27, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Share Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.39 · Expires 2036-02-26	Direct	66,000	Reported balance After 2026-02-26 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-02-26 · Grant · Acquired 66,000 · Balance 66,000 F1: Vests in substantially equal monthly installments over a one year period from the February 26, 2026 grant date. F2: Each American Depositary Share ("ADS") represents five ordinary shares, nominal value GBP 0.003 per ordinary share, of the Issuer.
Deferred Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	106,848	Reported balance After 2026-02-26 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2026-02-26 · Grant · Acquired 106,848 · Balance 106,848 F3: Deferred restricted stock units ("DRSU") are granted to non-executive directors who elected to receive DRSUs in the form of ADSs in lieu of annual cash compensation. DRSUs vest in substantially equal monthly installments over the plan year following the grant date. Payment of DRSUs in ADSs will generally be made 180 days following separation of service. F2: Each American Depositary Share ("ADS") represents five ordinary shares, nominal value GBP 0.003 per ordinary share, of the Issuer.

Filing footnotes · ownership attribution and instrument terms

F1: Vests in substantially equal monthly installments over a one year period from the February 26, 2026 grant date.

F2: Each American Depositary Share ("ADS") represents five ordinary shares, nominal value GBP 0.003 per ordinary share, of the Issuer.

F3: Deferred restricted stock units ("DRSU") are granted to non-executive directors who elected to receive DRSUs in the form of ADSs in lieu of annual cash compensation. DRSUs vest in substantially equal monthly installments over the plan year following the grant date. Payment of DRSUs in ADSs will generally be made 180 days following separation of service.

ONCOSEC MEDICAL Inc

Report date September 05, 2017 · Filed September 05, 2017

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.98 · Expires 2027-09-05	Direct	100,000	Reported balance After 2017-09-05 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2017-09-05 · Grant · Acquired 100,000 · Balance 100,000 F1: Vesting in 12 equal monthly increments, with the first 1/12th vesting on the first monthly anniversary of the Grant Date pursuant to the OncoSec Medical Incorporated 2011 Stock Incentive Plan.

Filing footnotes · ownership attribution and instrument terms

F1: Vesting in 12 equal monthly increments, with the first 1/12th vesting on the first monthly anniversary of the Grant Date pursuant to the OncoSec Medical Incorporated 2011 Stock Incentive Plan.

Serina Therapeutics, Inc.

Report date June 21, 2021 · Filed June 24, 2021

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $1.48 · Expires 2031-06-20	Direct	65,000	Reported balance After 2021-06-21 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2021-06-21 · Grant · Acquired 65,000 · Balance 65,000 F1: Options will vest and become exercisable in four equal quarterly installments on June 30, 2021, September 30, 2021, December 31, 2021, and March 31, 2022, provided that the grantee remains a director on the last day of the applicable calendar quarter.

Filing footnotes · ownership attribution and instrument terms

F1: Options will vest and become exercisable in four equal quarterly installments on June 30, 2021, September 30, 2021, December 31, 2021, and March 31, 2022, provided that the grantee remains a director on the last day of the applicable calendar quarter.

Skye Bioscience, Inc.

Report date March 31, 2026 · Filed April 02, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.62 · Expires 2036-03-31	Direct	75,000	Reported balance After 2026-03-31 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-03-31 · Grant · Acquired 75,000 · Balance 75,000 F1: The stock option vests in equal monthly installments over the one year period beginning March 31, 2026.

Filing footnotes · ownership attribution and instrument terms

F1: The stock option vests in equal monthly installments over the one year period beginning March 31, 2026.

Tectonic Therapeutic, Inc.

Report date June 06, 2023 · Filed June 08, 2023

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.09 · Expires 2033-06-05	Direct	17,643	Reported balance After 2023-06-06 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2023-06-06 · Grant · Acquired 17,643 · Balance 17,643 F1: The option shall vest in full upon the earlier of June 6, 2024 or the date of the Issuer's 2024 Annual Meeting of Stockholders, subject to the reporting person's continued service as a director through such vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: The option shall vest in full upon the earlier of June 6, 2024 or the date of the Issuer's 2024 Annual Meeting of Stockholders, subject to the reporting person's continued service as a director through such vesting date.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Dimension Therapeutics, Inc.

Report date November 07, 2017 · Filed November 07, 2017

Section 16 reporting ended · disclosed 2017-11-07. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.56 · Expires 2024-09-24	Direct	Reported balance After 2017-11-07 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2017-11-07 · Disposition to issuer · Disposed 481,696 · Balance 0 F1: This stock option, which vests over four years beginning September 23, 2014, at a rate of 25% after 12 months, and in 36 equal monthly installments thereafter, was assumed by Ultragenyx Pharmaceutical Inc. ("Ultragenyx"), and converted in accordance with the exchange ratio as set forth in the Agreement and Plan of Merger (the "Merger Agreement"), dated October 2, 2017, between the Issuer, Ultragenyx and Mystic River Merger Sub Inc., a direct, wholly-owned subsidiary of Ultragenyx.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.57 · Expires 2025-04-28	Direct	Reported balance After 2017-11-07 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2017-11-07 · Disposition to issuer · Disposed 74,375 · Balance 0 F2: This stock option, which vests over four years beginning September 23, 2014, at a rate of 25% after 12 months, and in 36 equal monthly installments thereafter, was assumed by Ultragenyx and converted in accordance with the exchange ratio as set forth in the Merger Agreement.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.09 · Expires 2025-06-02	Direct	Reported balance After 2017-11-07 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2017-11-07 · Disposition to issuer · Disposed 342,113 · Balance 0 F3: This stock option, which vests over four years beginning June 3, 2015, at a rate of 6.25% on September 23, 2015, and in 45 equal monthly installments thereafter, was assumed by Ultragenyx and converted in accordance with the exchange ratio as set forth in the Merger Agreement.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.14 · Expires 2026-01-31	Direct	Reported balance After 2017-11-07 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2017-11-07 · Disposition to issuer · Disposed 160,000 · Balance 0 F4: This stock option, which vests in 48 equal monthly installments beginning January 28, 2016, was assumed by Ultragenyx and converted in accordance with the exchange ratio as set forth in the Merger Agreement.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.90 · Expires 2027-01-31	Direct	Reported balance After 2017-11-07 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2017-11-07 · Disposition to issuer · Disposed 192,000 · Balance 0 F5: This stock option, which vests in 48 equal monthly installments beginning January 18, 2017, was assumed by Ultragenyx and converted in accordance with the exchange ratio as set forth in the Merger Agreement.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.35 · Expires 2027-07-02	Direct	Reported balance After 2017-11-07 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2017-11-07 · Disposition to issuer · Disposed 150,000 · Balance 0 F6: This option, which vests on December 31, 2018, subject to the Reporting Person's continued service to the Issuer on such date, was assumed by Ultragenyx and converted in accordance with the exchange ratio as set forth in the Merger Agreement.

Filing footnotes · ownership attribution and instrument terms

F1: This stock option, which vests over four years beginning September 23, 2014, at a rate of 25% after 12 months, and in 36 equal monthly installments thereafter, was assumed by Ultragenyx Pharmaceutical Inc. ("Ultragenyx"), and converted in accordance with the exchange ratio as set forth in the Agreement and Plan of Merger (the "Merger Agreement"), dated October 2, 2017, between the Issuer, Ultragenyx and Mystic River Merger Sub Inc., a direct, wholly-owned subsidiary of Ultragenyx.

F2: This stock option, which vests over four years beginning September 23, 2014, at a rate of 25% after 12 months, and in 36 equal monthly installments thereafter, was assumed by Ultragenyx and converted in accordance with the exchange ratio as set forth in the Merger Agreement.

F3: This stock option, which vests over four years beginning June 3, 2015, at a rate of 6.25% on September 23, 2015, and in 45 equal monthly installments thereafter, was assumed by Ultragenyx and converted in accordance with the exchange ratio as set forth in the Merger Agreement.

F4: This stock option, which vests in 48 equal monthly installments beginning January 28, 2016, was assumed by Ultragenyx and converted in accordance with the exchange ratio as set forth in the Merger Agreement.

F5: This stock option, which vests in 48 equal monthly installments beginning January 18, 2017, was assumed by Ultragenyx and converted in accordance with the exchange ratio as set forth in the Merger Agreement.

F6: This option, which vests on December 31, 2018, subject to the Reporting Person's continued service to the Issuer on such date, was assumed by Ultragenyx and converted in accordance with the exchange ratio as set forth in the Merger Agreement.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
March 31, 2026 Filed Apr 2, 2026 22:20 UTC	Skye Bioscience, Inc. SKYE · Entity 8098	GrantStock Option (Right to Buy) · Derivative	75,000	$0.00 Strike: $0.62	$0.00	Disclosure SEC source: 0001628280-26-023354 · wk-form4_1775168412.xml · derivative · entry 1 Jenkins Annalisa · CIK 0001639481 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2036-03-31 F1 · derivative.exercise_date: The stock option vests in equal monthly installments over the one year period beginning March 31, 2026. Read SEC document
February 26, 2026 Filed Feb 27, 2026 21:30 UTC	Mereo BioPharma Group plc MREO · Entity 7264	GrantDeferred Restricted Stock Units · Derivative	106,848	Not disclosed	Not disclosed	Disclosure SEC source: 0001193125-26-082835 · ownership.xml · derivative · entry 2 Jenkins Annalisa · CIK 0001639481 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 106,848 Underlying: American Depository Shares · 106,848 shares Expires not disclosed F3 · derivative.exercise_price: Deferred restricted stock units ("DRSU") are granted to non-executive directors who elected to receive DRSUs in the form of ADSs in lieu of annual cash compensation. DRSUs vest in substantially equal monthly installments over the plan year following the grant date. Payment of DRSUs in ADSs will generally be made 180 days following separation of service. F3 · price: Deferred restricted stock units ("DRSU") are granted to non-executive directors who elected to receive DRSUs in the form of ADSs in lieu of annual cash compensation. DRSUs vest in substantially equal monthly installments over the plan year following the grant date. Payment of DRSUs in ADSs will generally be made 180 days following separation of service. F3 · derivative.exercise_date: Deferred restricted stock units ("DRSU") are granted to non-executive directors who elected to receive DRSUs in the form of ADSs in lieu of annual cash compensation. DRSUs vest in substantially equal monthly installments over the plan year following the grant date. Payment of DRSUs in ADSs will generally be made 180 days following separation of service. F3 · derivative.expiration_date: Deferred restricted stock units ("DRSU") are granted to non-executive directors who elected to receive DRSUs in the form of ADSs in lieu of annual cash compensation. DRSUs vest in substantially equal monthly installments over the plan year following the grant date. Payment of DRSUs in ADSs will generally be made 180 days following separation of service. F2 · derivative.underlying: Each American Depositary Share ("ADS") represents five ordinary shares, nominal value GBP 0.003 per ordinary share, of the Issuer. Read SEC document
February 26, 2026 Filed Feb 27, 2026 21:30 UTC	Mereo BioPharma Group plc MREO · Entity 7264	GrantShare Options (Right to buy) · Derivative	66,000	$0.00 Strike: $0.39	$0.00	Disclosure SEC source: 0001193125-26-082835 · ownership.xml · derivative · entry 1 Jenkins Annalisa · CIK 0001639481 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 66,000 Underlying: American Depositary Shares · 66,000 shares Expires 2036-02-26 F1 · derivative.exercise_date: Vests in substantially equal monthly installments over a one year period from the February 26, 2026 grant date. F2 · derivative.underlying: Each American Depositary Share ("ADS") represents five ordinary shares, nominal value GBP 0.003 per ordinary share, of the Issuer. Read SEC document
February 06, 2026 Filed Feb 10, 2026 01:54 UTC	Skye Bioscience, Inc. SKYE · Entity 8098	GrantStock Option (Right to Buy) · Derivative	35,000	$0.00 Strike: $0.82	$0.00	Disclosure SEC source: 0001628280-26-006621 · wk-form4_1770688465.xml · derivative · entry 1 Jenkins Annalisa · CIK 0001639481 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2036-02-06 F1 · derivative.exercise_date: The stock option vests in equal monthly installments over the one-year period beginning January 19, 2026. Read SEC document
June 12, 2025 Filed Jun 13, 2025 12:16 UTC	COMPASS Pathways plc CMPS · Entity 4567	GrantShare Option (Right to Buy) · Derivative	26,000	$0.00 Strike: $4.52	$0.00	Disclosure SEC source: 0001816590-25-000069 · wk-form4_1749816998.xml · derivative · entry 1 Jenkins Annalisa · CIK 0001639481 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,000 Underlying: Ordinary Shares · 26,000 shares Expires 2035-06-11 F1 · derivative.exercise_date: The shares underlying this option vest in full upon the earlier to occur of (i) the first anniversary of the date of grant or (ii) the date of COMPASS Pathways plc's Annual General Meeting of Shareholders in 2026. F2 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document
February 24, 2025 Filed Feb 26, 2025 22:51 UTC	Skye Bioscience, Inc. SKYE · Entity 8098	GrantStock Option (Right to Buy) · Derivative	35,000	$0.00 Strike: $2.89	$0.00	Disclosure SEC source: 0001516551-25-000016 · wk-form4_1740610301.xml · derivative · entry 1 Jenkins Annalisa · CIK 0001639481 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2035-02-25 F1 · derivative.exercise_date: The stock option vests in equal monthly installments over the one year period beginning February 21, 2025. Read SEC document
February 05, 2025 Filed Feb 6, 2025 21:30 UTC	Mereo BioPharma Group plc MREO · Entity 7264	GrantDeferred Restricted Stock Units · Derivative	15,243	Not disclosed	Not disclosed	Disclosure SEC source: 0000950170-25-015417 · ownership.xml · derivative · entry 2 Jenkins Annalisa · CIK 0001639481 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,243 Underlying: American Depository Shares · 15,243 shares Expires not disclosed F3 · derivative.exercise_price: Deferred restricted stock units ("DRSU") are granted to non-executive directors who elected to receive DRSUs in the form of ADSs in lieu of annual cash compensation. DRSUs vest in substantially equal monthly installments over the plan year following the grant date. Payment of DRSUs in ADSs will generally be made 180 days following separation of service. F3 · price: Deferred restricted stock units ("DRSU") are granted to non-executive directors who elected to receive DRSUs in the form of ADSs in lieu of annual cash compensation. DRSUs vest in substantially equal monthly installments over the plan year following the grant date. Payment of DRSUs in ADSs will generally be made 180 days following separation of service. F3 · derivative.exercise_date: Deferred restricted stock units ("DRSU") are granted to non-executive directors who elected to receive DRSUs in the form of ADSs in lieu of annual cash compensation. DRSUs vest in substantially equal monthly installments over the plan year following the grant date. Payment of DRSUs in ADSs will generally be made 180 days following separation of service. F3 · derivative.expiration_date: Deferred restricted stock units ("DRSU") are granted to non-executive directors who elected to receive DRSUs in the form of ADSs in lieu of annual cash compensation. DRSUs vest in substantially equal monthly installments over the plan year following the grant date. Payment of DRSUs in ADSs will generally be made 180 days following separation of service. F2 · derivative.underlying: Each American Depositary Share ("ADS") represents five ordinary shares, nominal value GBP 0.003 per ordinary share, of the Issuer Read SEC document
February 05, 2025 Filed Feb 6, 2025 21:30 UTC	Mereo BioPharma Group plc MREO · Entity 7264	GrantShare Options (Right to buy) · Derivative	55,000	$0.00 Strike: $3.16	$0.00	Disclosure SEC source: 0000950170-25-015417 · ownership.xml · derivative · entry 1 Jenkins Annalisa · CIK 0001639481 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 55,000 Underlying: American Depositary Shares · 55,000 shares Expires 2035-02-05 F1 · derivative.exercise_date: Vests in substantially equal monthly installments over a one year period from the February 5, 2025 grant date F2 · derivative.underlying: Each American Depositary Share ("ADS") represents five ordinary shares, nominal value GBP 0.003 per ordinary share, of the Issuer Read SEC document
October 28, 2024 Filed Oct 31, 2024 00:25 UTC	Skye Bioscience, Inc. SKYE · Entity 8098	GrantStock Option (Right to Buy) · Derivative	70,000	$0.00 Strike: $5.15	$0.00	Disclosure SEC source: 0001516551-24-000096 · wk-form4_1730334295.xml · derivative · entry 1 Jenkins Annalisa · CIK 0001639481 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 70,000 Underlying: Common Stock · 70,000 shares Expires 2034-10-27 F1 · derivative.exercise_date: The stock option vests in equal monthly installments over the one year period beginning October 28, 2024. Read SEC document
August 01, 2024 Filed Aug 5, 2024 12:28 UTC	COMPASS Pathways plc CMPS · Entity 4567	Tax withholdingOrdinary Shares	161	$6.88	$1,107.68	Disclosure SEC source: 0001628280-24-034539 · wk-form4_1722860886.xml · nonDerivative · entry 1 Jenkins Annalisa · CIK 0001639481 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,480 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · balance_after: Represents shares withheld by the Issuer upon vesting of restricted share units to satisfy tax withholding obligations. Read SEC document
May 09, 2024 Filed May 13, 2024 10:45 UTC	COMPASS Pathways plc CMPS · Entity 4567	GrantShare Option (Right to Buy) · Derivative	26,000	$0.00 Strike: $8.54	$0.00	Disclosure SEC source: 0001816590-24-000097 · wk-form4_1715597104.xml · derivative · entry 1 Jenkins Annalisa · CIK 0001639481 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,000 Underlying: Ordinary Shares · 26,000 shares Expires 2034-05-08 F1 · derivative.exercise_date: The shares underlying this option vest in full upon the earlier to occur of (i) the first anniversary of the date of grant or (ii) the date of COMPASS Pathways plc's Annual General Meeting of Shareholders in 2025. F2 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document
May 01, 2024 Filed May 3, 2024 12:13 UTC	COMPASS Pathways plc CMPS · Entity 4567	Tax withholdingOrdinary Shares	211	$8.48	$1,789.28	Disclosure SEC source: 0001816590-24-000077 · wk-form4_1714738380.xml · nonDerivative · entry 1 Jenkins Annalisa · CIK 0001639481 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,641 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · shares: Represents shares withheld by the Issuer upon vesting of restricted share units to satisfy tax withholding obligations. Read SEC document
February 29, 2024 Filed Mar 4, 2024 23:01 UTC	Skye Bioscience, Inc. SKYE · Entity 8098	GrantStock Option (Right to Buy) · Derivative	40,000	$0.00 Strike: $14.56	$0.00	Disclosure SEC source: 0001516551-24-000038 · wk-form4_1709593247.xml · derivative · entry 1 Jenkins Annalisa · CIK 0001639481 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2034-03-01 F1 · derivative.exercise_date: The option grant shall be exercisable for a price of $14.56 per option share for ten years from February 29, 2024 and the options will vest in equal monthly installments over the one year period beginning February 29, 2024. Read SEC document
February 08, 2024 Filed Feb 9, 2024 21:15 UTC	Mereo BioPharma Group plc MREO · Entity 7264	GrantDeferred Restricted Stock Units · Derivative	14,947	Not disclosed	Not disclosed	Disclosure SEC source: 0000950170-24-013273 · ownership.xml · derivative · entry 2 Jenkins Annalisa · CIK 0001639481 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,947 Underlying: American Depository Shares · 14,947 shares Expires not disclosed F3 · derivative.exercise_price: Deferred restricted stock units ("DRSU") are granted to non-executive directors who elected to receive DRSUs in the form of ADSs in lieu of annual cash compensation. DRSUs vest in substantially equal monthly installments over the plan year following the grant date. Payment of DRSUs in ADSs will generally be made 180 days following separation of service. F3 · price: Deferred restricted stock units ("DRSU") are granted to non-executive directors who elected to receive DRSUs in the form of ADSs in lieu of annual cash compensation. DRSUs vest in substantially equal monthly installments over the plan year following the grant date. Payment of DRSUs in ADSs will generally be made 180 days following separation of service. F3 · derivative.exercise_date: Deferred restricted stock units ("DRSU") are granted to non-executive directors who elected to receive DRSUs in the form of ADSs in lieu of annual cash compensation. DRSUs vest in substantially equal monthly installments over the plan year following the grant date. Payment of DRSUs in ADSs will generally be made 180 days following separation of service. F3 · derivative.expiration_date: Deferred restricted stock units ("DRSU") are granted to non-executive directors who elected to receive DRSUs in the form of ADSs in lieu of annual cash compensation. DRSUs vest in substantially equal monthly installments over the plan year following the grant date. Payment of DRSUs in ADSs will generally be made 180 days following separation of service. F2 · derivative.underlying: Each American Depositary Share ("ADS") represents five ordinary shares, nominal value GBP 0.003 per ordinary share, of the Issuer. Read SEC document
February 08, 2024 Filed Feb 9, 2024 21:15 UTC	Mereo BioPharma Group plc MREO · Entity 7264	GrantShare Options (Right to buy) · Derivative	45,000	$0.00 Strike: $3.87	$0.00	Disclosure SEC source: 0000950170-24-013273 · ownership.xml · derivative · entry 1 Jenkins Annalisa · CIK 0001639481 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,000 Underlying: American Depository Shares · 45,000 shares Expires 2034-02-08 F1 · derivative.exercise_date: Vests in substantially equal monthly installments over a one year period from the February 8, 2024 grant date. F2 · derivative.underlying: Each American Depositary Share ("ADS") represents five ordinary shares, nominal value GBP 0.003 per ordinary share, of the Issuer. Read SEC document
February 01, 2024 Filed Feb 5, 2024 22:10 UTC	COMPASS Pathways plc CMPS · Entity 4567	Tax withholdingOrdinary Shares	175	$11.34	$1,984.50	Disclosure SEC source: 0001816590-24-000026 · wk-form4_1707170969.xml · nonDerivative · entry 1 Jenkins Annalisa · CIK 0001639481 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,852 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · shares: Represents shares withheld by the Issuer upon vesting of restricted share units to satisfy tax withholding obligations. Read SEC document
November 01, 2023 Filed Nov 2, 2023 13:06 UTC	COMPASS Pathways plc CMPS · Entity 4567	Tax withholdingOrdinary Shares	143	$5.78	$826.54	Disclosure SEC source: 0001816590-23-000137 · wk-form4_1698930397.xml · nonDerivative · entry 1 Jenkins Annalisa · CIK 0001639481 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,027 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · shares: Represents shares withheld by the Issuer upon vesting of restricted share units to satisfy tax withholding obligations. F2 · balance_after: Represents shares withheld by the Issuer upon vesting of restricted share units to satisfy tax withholding obligations. Read SEC document
August 01, 2023 Filed Aug 3, 2023 22:50 UTC	COMPASS Pathways plc CMPS · Entity 4567	Tax withholdingOrdinary Shares	161	$8.95	$1,440.95	Disclosure SEC source: 0001816590-23-000095 · wk-form4_1691103039.xml · nonDerivative · entry 1 Jenkins Annalisa · CIK 0001639481 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,170 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · shares: Represents shares withheld by the Issuer upon vesting of restricted share units to satisfy tax withholding obligations. Read SEC document
June 06, 2023 Filed Jun 8, 2023 20:26 UTC	Tectonic Therapeutic, Inc. AVRO · Entity 5328	GrantStock Option (Right to Buy) · Derivative	17,643	$0.00 Strike: $1.09	$0.00	Disclosure SEC source: 0001127602-23-018282 · form4.xml · derivative · entry 1 Jenkins Annalisa · CIK 0001639481 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,643 Underlying: Common Stock · 17,643 shares Expires 2033-06-05 F1 · derivative.exercise_date: The option shall vest in full upon the earlier of June 6, 2024 or the date of the Issuer's 2024 Annual Meeting of Stockholders, subject to the reporting person's continued service as a director through such vesting date. Read SEC document
June 02, 2023 Filed Jun 6, 2023 20:23 UTC	COMPASS Pathways plc CMPS · Entity 4567	GrantShare Option (Right to Buy) · Derivative	26,000	$0.00 Strike: $7.88	$0.00	Disclosure SEC source: 0001816590-23-000085 · wk-form4_1686083021.xml · derivative · entry 1 Jenkins Annalisa · CIK 0001639481 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,000 Underlying: Ordinary Shares · 26,000 shares Expires 2033-06-01 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · derivative.exercise_date: The shares underlying this option vest in full upon the earlier to occur of (i) the first anniversary of the date of grant or (ii) the date of COMPASS Pathways plc's Annual Meeting of Shareholders in 2024. Read SEC document
May 02, 2023 Filed May 4, 2023 12:25 UTC	COMPASS Pathways plc CMPS · Entity 4567	Tax withholdingOrdinary Shares	25	$7.97	$199.25	Disclosure SEC source: 0001816590-23-000067 · wf-form4_168320312036793.xml · nonDerivative · entry 1 Jenkins Annalisa · CIK 0001639481 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,331 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · shares: Represents shares withheld by the Issuer upon vesting of restricted share units to satisfy tax withholding obligations. Read SEC document
June 16, 2022 Filed Jun 17, 2022 20:08 UTC	COMPASS Pathways plc CMPS · Entity 4567	GrantShare Option (Right to Buy) · Derivative	17,000	$0.00 Strike: $9.41	$0.00	Disclosure SEC source: 0001816590-22-000056 · wf-form4_165549647968752.xml · derivative · entry 1 Jenkins Annalisa · CIK 0001639481 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,000 Underlying: Ordinary Shares · 17,000 shares Expires 2032-06-15 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · derivative.exercise_date: The shares underlying this option vest in full upon the earlier to occur of (i) the first anniversary of the date of grant or (ii) the date of COMPASS Pathways plc's Annual Meeting of Shareholders in 2023. Read SEC document
June 08, 2022 Filed Jun 10, 2022 20:38 UTC	Tectonic Therapeutic, Inc. AVRO · Entity 5328	GrantStock Option (Right to Buy) · Derivative	17,478	$0.00 Strike: $1.06	$0.00	Disclosure SEC source: 0001127602-22-017242 · form4.xml · derivative · entry 2 Jenkins Annalisa · CIK 0001639481 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,478 Underlying: Common Stock · 17,478 shares Expires 2032-06-07 F1 · derivative.exercise_date: The option shall vest in full upon the earlier of June 8, 2023 or the date of the Issuer's 2023 Annual Meeting of Stockholders, subject to the reporting person's continued service as a director through such vesting date. Read SEC document
June 08, 2022 Filed Jun 10, 2022 20:38 UTC	Tectonic Therapeutic, Inc. AVRO · Entity 5328	GrantStock Option (Right to Buy) · Derivative	17,478	$0.00 Strike: $1.06	$0.00	Disclosure SEC source: 0001127602-22-017242 · form4.xml · derivative · entry 1 Jenkins Annalisa · CIK 0001639481 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,478 Underlying: Common Stock · 17,478 shares Expires 2032-06-07 F1 · derivative.exercise_date: The option shall vest in full upon the earlier of June 8, 2023 or the date of the Issuer's 2023 Annual Meeting of Stockholders, subject to the reporting person's continued service as a director through such vesting date. Read SEC document
March 29, 2022 Filed Mar 31, 2022 18:09 UTC	COMPASS Pathways plc CMPS · Entity 4567	SaleOrdinary Shares	3,384	$12.48	$42,232.32	Disclosure SEC source: 0001816590-22-000016 · wf-form4_164875016391913.xml · nonDerivative · entry 1 Jenkins Annalisa · CIK 0001639481 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,356 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · shares: Shares were sold to satisfy payment of a tax liability upon Restricted Share Units ("RSUs") vesting. F3 · balance_after: Includes 23,740 RSUs granted under the Issuer's 2020 Share Option and Incentive Plan. Each RSU represents a contingent right to receive one Ordinary Share. 25% of the RSUs vested on August 12,2021, with the remainder vesting in twelve equal quarterly installments thereafter. Read SEC document
June 21, 2021 Filed Jun 24, 2021 01:50 UTC	Serina Therapeutics, Inc. AGE · Entity 9581	GrantOption to Purchase Common Stock · Derivative	65,000	$0.00 Strike: $1.48	$0.00	Disclosure SEC source: 0001209191-21-042896 · doc4.xml · derivative · entry 1 Jenkins Annalisa · CIK 0001639481 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,000 Underlying: Common Stock · 65,000 shares Expires 2031-06-20 F1 · derivative.exercise_date: Options will vest and become exercisable in four equal quarterly installments on June 30, 2021, September 30, 2021, December 31, 2021, and March 31, 2022, provided that the grantee remains a director on the last day of the applicable calendar quarter. Read SEC document
June 10, 2021 Filed Jun 14, 2021 21:40 UTC	Tectonic Therapeutic, Inc. AVRO · Entity 5328	GrantStock Option (Right to Buy) · Derivative	17,438	$0.00 Strike: $9.63	$0.00	Disclosure SEC source: 0001127602-21-019820 · form4.xml · derivative · entry 1 Jenkins Annalisa · CIK 0001639481 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,438 Underlying: Common Stock · 17,438 shares Expires 2031-06-09 F1 · derivative.exercise_date: The option shall vest in full upon the earlier of June 10, 2022 or the date of the Issuer's 2022 Annual Meeting of Stockholders, subject to the reporting person's continued service as a director through such vesting date. Read SEC document
June 04, 2020 Filed Jun 5, 2020 21:13 UTC	Tectonic Therapeutic, Inc. AVRO · Entity 5328	GrantStock Option (Right to Buy) · Derivative	14,000	$0.00 Strike: $21.91	$0.00	Disclosure SEC source: 0001127602-20-019020 · form4.xml · derivative · entry 1 Jenkins Annalisa · CIK 0001639481 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,000 Underlying: Common Stock · 14,000 shares Expires 2030-06-03 F1 · derivative.exercise_date: The option shall vest in full upon the earlier of June 4, 2021 or the date of the Issuer's 2021 Annual Meeting of Stockholders, subject to the reporting person's continued service as a director through such vesting date. Read SEC document
June 13, 2019 Filed Jun 17, 2019 20:31 UTC	ARDELYX, INC. ARDX · Entity 4972	GrantStock Option (Right to Buy) · Derivative	50,000	$0.00 Strike: $2.74	$0.00	Disclosure SEC source: 0001567619-19-013480 · doc1.xml · derivative · entry 2 Jenkins Annalisa · CIK 0001639481 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2029-06-13 F2 · shares: The option was issued pursuant to the Issuer's Non-Employee Director Compensation Program. F3 · derivative.exercise_date: The option vests with respect to 1/12th of the shares subject thereto on each monthly anniversary of the grant date, which vesting will accelerate in full on the date of the next annual stockholder's meeting to the extent unvested as of such date, subject to continued service through each applicable vesting date. Read SEC document
June 13, 2019 Filed Jun 17, 2019 20:31 UTC	ARDELYX, INC. ARDX · Entity 4972	GrantCommon Stock	20,072	$0.00	$0.00	Disclosure SEC source: 0001567619-19-013480 · doc1.xml · nonDerivative · entry 1 Jenkins Annalisa · CIK 0001639481 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,471 F1 · shares: The shares were issued pursuant to the Issuer's Non-Employee Director Compensation Program. The Reporting Person elected to receive stock in lieu of cash as permitted under the program. Read SEC document
June 11, 2019 Filed Jun 13, 2019 21:09 UTC	Tectonic Therapeutic, Inc. AVRO · Entity 5328	GrantStock Option (Right to Buy) · Derivative	9,675	$0.00 Strike: $13.60	$0.00	Disclosure SEC source: 0000899243-19-016855 · doc4.xml · derivative · entry 1 Jenkins Annalisa · CIK 0001639481 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,675 Underlying: Common Stock · 9,675 shares Expires 2029-06-10 F1 · derivative.exercise_date: The option shall vest in full upon the earlier of June 11, 2020 or the date of the Issuer's 2020 Annual Meeting of Stockholders, subject to the reporting person's continued service as a director through such vesting date. Read SEC document
March 11, 2019 Filed Mar 13, 2019 20:09 UTC	Serina Therapeutics, Inc. AGE · Entity 9581	GrantOption to Purchase Common Stock · Derivative	100,000	$0.00 Strike: $4.28	$0.00	Disclosure SEC source: 0000908662-19-000093 · edgar.xml · derivative · entry 1 Jenkins Annalisa · CIK 0001639481 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2029-03-10 F1 · derivative.exercise_date: Options will become exercisable in four equal quarterly installments from the date of grant on March 11, 2019 provided that the grantee remains a director on the last day of the applicable calendar quarter. Read SEC document
June 13, 2018 Filed Jun 15, 2018 23:08 UTC	ARDELYX, INC. ARDX · Entity 4972	GrantStock Option (Right to Buy) · Derivative	15,000	$0.00 Strike: $4.03	$0.00	Disclosure SEC source: 0001140361-18-028865 · doc1.xml · derivative · entry 2 Jenkins Annalisa · CIK 0001639481 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2028-06-13 F2 · shares: The option was issued pursuant to the Issuer's Non-Employee Director Compensation Program. F3 · derivative.exercise_date: The option vests with respect to 1/12th of the shares subject thereto on each monthly anniversary of the grant date, which vesting will accelerate in full on the date of the next annual stockholder's meeting to the extent unvested as of such date, subject to continued service through each applicable vesting date. Read SEC document
June 13, 2018 Filed Jun 15, 2018 23:08 UTC	ARDELYX, INC. ARDX · Entity 4972	GrantCommon Stock	13,399	$0.00	$0.00	Disclosure SEC source: 0001140361-18-028865 · doc1.xml · nonDerivative · entry 1 Jenkins Annalisa · CIK 0001639481 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,399 F1 · shares: The shares were issued pursuant to the Issuer's Non-Employee Director Compensation Program. The Reporting Person elected to receive stock in lieu of cash as permitted under the program. Read SEC document
November 07, 2017 Filed Nov 7, 2017 17:08 UTC	Dimension Therapeutics, Inc. DMTX · Entity 172012	Disposition to issuerStock Option (Right to Buy) · Derivative	150,000	Not disclosed Strike: $1.35	Not disclosed	Disclosure SEC source: 0001209191-17-059629 · doc4.xml · derivative · entry 6 Jenkins Annalisa · CIK 0001639481 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 150,000 shares Expires 2027-07-02 F6 · price: This option, which vests on December 31, 2018, subject to the Reporting Person's continued service to the Issuer on such date, was assumed by Ultragenyx and converted in accordance with the exchange ratio as set forth in the Merger Agreement. F6 · derivative.exercise_date: This option, which vests on December 31, 2018, subject to the Reporting Person's continued service to the Issuer on such date, was assumed by Ultragenyx and converted in accordance with the exchange ratio as set forth in the Merger Agreement. Read SEC document
November 07, 2017 Filed Nov 7, 2017 17:08 UTC	Dimension Therapeutics, Inc. DMTX · Entity 172012	Disposition to issuerStock Option (Right to Buy) · Derivative	192,000	Not disclosed Strike: $1.90	Not disclosed	Disclosure SEC source: 0001209191-17-059629 · doc4.xml · derivative · entry 5 Jenkins Annalisa · CIK 0001639481 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 192,000 shares Expires 2027-01-31 F5 · price: This stock option, which vests in 48 equal monthly installments beginning January 18, 2017, was assumed by Ultragenyx and converted in accordance with the exchange ratio as set forth in the Merger Agreement. F5 · derivative.exercise_date: This stock option, which vests in 48 equal monthly installments beginning January 18, 2017, was assumed by Ultragenyx and converted in accordance with the exchange ratio as set forth in the Merger Agreement. Read SEC document
November 07, 2017 Filed Nov 7, 2017 17:08 UTC	Dimension Therapeutics, Inc. DMTX · Entity 172012	Disposition to issuerStock Option (Right to Buy) · Derivative	160,000	Not disclosed Strike: $7.14	Not disclosed	Disclosure SEC source: 0001209191-17-059629 · doc4.xml · derivative · entry 4 Jenkins Annalisa · CIK 0001639481 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 160,000 shares Expires 2026-01-31 F4 · price: This stock option, which vests in 48 equal monthly installments beginning January 28, 2016, was assumed by Ultragenyx and converted in accordance with the exchange ratio as set forth in the Merger Agreement. F4 · derivative.exercise_date: This stock option, which vests in 48 equal monthly installments beginning January 28, 2016, was assumed by Ultragenyx and converted in accordance with the exchange ratio as set forth in the Merger Agreement. Read SEC document
November 07, 2017 Filed Nov 7, 2017 17:08 UTC	Dimension Therapeutics, Inc. DMTX · Entity 172012	Disposition to issuerStock Option (Right to Buy) · Derivative	342,113	Not disclosed Strike: $4.09	Not disclosed	Disclosure SEC source: 0001209191-17-059629 · doc4.xml · derivative · entry 3 Jenkins Annalisa · CIK 0001639481 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 342,113 shares Expires 2025-06-02 F3 · price: This stock option, which vests over four years beginning June 3, 2015, at a rate of 6.25% on September 23, 2015, and in 45 equal monthly installments thereafter, was assumed by Ultragenyx and converted in accordance with the exchange ratio as set forth in the Merger Agreement. F3 · derivative.exercise_date: This stock option, which vests over four years beginning June 3, 2015, at a rate of 6.25% on September 23, 2015, and in 45 equal monthly installments thereafter, was assumed by Ultragenyx and converted in accordance with the exchange ratio as set forth in the Merger Agreement. Read SEC document
November 07, 2017 Filed Nov 7, 2017 17:08 UTC	Dimension Therapeutics, Inc. DMTX · Entity 172012	Disposition to issuerStock Option (Right to Buy) · Derivative	74,375	Not disclosed Strike: $3.57	Not disclosed	Disclosure SEC source: 0001209191-17-059629 · doc4.xml · derivative · entry 2 Jenkins Annalisa · CIK 0001639481 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 74,375 shares Expires 2025-04-28 F2 · price: This stock option, which vests over four years beginning September 23, 2014, at a rate of 25% after 12 months, and in 36 equal monthly installments thereafter, was assumed by Ultragenyx and converted in accordance with the exchange ratio as set forth in the Merger Agreement. F2 · derivative.exercise_date: This stock option, which vests over four years beginning September 23, 2014, at a rate of 25% after 12 months, and in 36 equal monthly installments thereafter, was assumed by Ultragenyx and converted in accordance with the exchange ratio as set forth in the Merger Agreement. Read SEC document
November 07, 2017 Filed Nov 7, 2017 17:08 UTC	Dimension Therapeutics, Inc. DMTX · Entity 172012	Disposition to issuerStock Option (Right to Buy) · Derivative	481,696	Not disclosed Strike: $0.56	Not disclosed	Disclosure SEC source: 0001209191-17-059629 · doc4.xml · derivative · entry 1 Jenkins Annalisa · CIK 0001639481 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 481,696 shares Expires 2024-09-24 F1 · price: This stock option, which vests over four years beginning September 23, 2014, at a rate of 25% after 12 months, and in 36 equal monthly installments thereafter, was assumed by Ultragenyx Pharmaceutical Inc. ("Ultragenyx"), and converted in accordance with the exchange ratio as set forth in the Agreement and Plan of Merger (the "Merger Agreement"), dated October 2, 2017, between the Issuer, Ultragenyx and Mystic River Merger Sub Inc., a direct, wholly-owned subsidiary of Ultragenyx. F1 · derivative.exercise_date: This stock option, which vests over four years beginning September 23, 2014, at a rate of 25% after 12 months, and in 36 equal monthly installments thereafter, was assumed by Ultragenyx Pharmaceutical Inc. ("Ultragenyx"), and converted in accordance with the exchange ratio as set forth in the Agreement and Plan of Merger (the "Merger Agreement"), dated October 2, 2017, between the Issuer, Ultragenyx and Mystic River Merger Sub Inc., a direct, wholly-owned subsidiary of Ultragenyx. Read SEC document
September 05, 2017 Filed Sep 5, 2017 06:18 UTC	ONCOSEC MEDICAL Inc ONCS · Entity 117092	GrantStock Option (Right to Buy) · Derivative	100,000	$0.00 Strike: $0.98	$0.00	Disclosure SEC source: 0001493152-17-010200 · form4.xml · derivative · entry 1 Jenkins Annalisa · CIK 0001639481 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2027-09-05 F1 · date: Vesting in 12 equal monthly increments, with the first 1/12th vesting on the first monthly anniversary of the Grant Date pursuant to the OncoSec Medical Incorporated 2011 Stock Incentive Plan. F1 · derivative.exercise_date: Vesting in 12 equal monthly increments, with the first 1/12th vesting on the first monthly anniversary of the Grant Date pursuant to the OncoSec Medical Incorporated 2011 Stock Incentive Plan. Read SEC document
July 03, 2017 Filed Jul 5, 2017 17:47 UTC	Dimension Therapeutics, Inc. DMTX · Entity 172012	GrantStock Option (Right to Buy) · Derivative	150,000	$0.00 Strike: $1.35	$0.00	Disclosure SEC source: 0001209191-17-043425 · doc4.xml · derivative · entry 1 Jenkins Annalisa · CIK 0001639481 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2027-07-02 F1 · derivative.exercise_date: This option shall vest on December 31, 2018, subject to the Reporting Person's continued service to the Issuer on such date. Read SEC document
June 07, 2017 Filed Jun 12, 2017 16:26 UTC	ARDELYX, INC. ARDX · Entity 4972	GrantStock Option (Right to Buy) · Derivative	15,000	$0.00 Strike: $4.30	$0.00	Disclosure SEC source: 0001140361-17-024640 · doc1.xml · derivative · entry 1 Jenkins Annalisa · CIK 0001639481 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2027-06-07 F1 · shares: The option was issued pursuant to the Issuer's Non-Employee Director Compensation Program. F2 · derivative.exercise_date: The option vests with respect to 1/12th of the shares subject thereto on each monthly anniversary of the grant date, which vesting will accelerate in full on the date of the next annual stockholder's meeting to the extent unvested as of such date, subject to continued service through each applicable vesting date. Read SEC document
February 01, 2017 Filed Feb 3, 2017 16:52 UTC	Dimension Therapeutics, Inc. DMTX · Entity 172012	GrantStock Option (Right to Buy) · Derivative	192,000	$0.00 Strike: $1.90	$0.00	Disclosure SEC source: 0001209191-17-007681 · doc4.xml · derivative · entry 1 Jenkins Annalisa · CIK 0001639481 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 192,000 Underlying: Common Stock · 192,000 shares Expires 2027-01-31 F1 · derivative.exercise_date: This stock option vests in forty-eight (48) equal monthly installments beginning on January 18, 2017. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.